Drugs / Nanogam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01985373 | Dec 2013 → Mar 2015 | immunodeficiency disease | Prothya Biosolutions | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06223984 Comparator | Mar → Nov 2020 | — | Konya City Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanogam | “Sanquin developed a 100 mg/ml IVIg product (Nanogam 100 mg/ml).” NCT01985373 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (400 mg/kg/day for 5 days)” NCT06223984 ↗ |
| Route | Intravenous | “One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml” NCT01985373 ↗ |